Page 1723 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 95 Practical Aspects of Hematologic Stem Cell Harvesting and Mobilization 1530.e3

79. Weaver CH, Schulman KA, Wilson-Relyea G, et al: Randomized trial 97. Elliott C, Samson DM, Armitage S, et al: When to harvest peripheral-
of filgrastim, sargramostim, or sequential sargramostim and filgrastim blood stem cells after mobilization therapy: prediction of CD34-positive
after myelosuppressive chemotherapy for the harvesting of peripheral- cell yield by preceding day CD34-positive concentration in peripheral
blood stem cells. J Clin Oncol 18(1):43–53, 2000. blood. J Clin Oncol 14(3):970–973, 1996.
80. Villeval J-L, Dührsen U, Morstyn G, et al: Effect of recombinant human 98. Liles WC, Broxmeyer HE, Rodger E, et al: Mobilization of hemato-
granulocyte-macrophage colony stimulating factor on progenitor cells poietic progenitor cells in healthy volunteers by AMD3100, a CXCR4
in patients with advanced malignancies. Br J Haematol 74(1):36–44, antagonist. Blood 102(8):2728–2730, 2003.
1990. 99. Lemery SJ, Hsieh MM, Smith A, et al: A pilot study evaluating
81. Narayanasami U, Kanteti R, Morelli J, et al: Randomized trial of the safety and CD34+ cell mobilizing activity of escalating doses
filgrastim versus chemotherapy and filgrastim mobilization of hemato- of plerixafor in healthy volunteers. Br J Haematol 153(1):66–75,
poietic progenitor cells for rescue in autologous transplantation. Blood 2011.
98(7):2059–2064, 2001. 100. Stewart DA, Smith C, MacFarland R, et al: Pharmacokinetics and phar-
82. Demirer T, Buckner CD, Storer B, et al: Effect of different chemo- macodynamics of plerixafor in patients with non-Hodgkin lymphoma
therapy regimens on peripheral-blood stem-cell collections in patients and multiple myeloma. Biol Blood Marrow Transplant 15(1):39–46,
with breast cancer receiving granulocyte colony-stimulating factor. J 2009.
Clin Oncol 15(2):684–690, 1997. 101. Shi PA, Miller LK, Isola LM: Prospective study of mobilization kinetics
83. Rollins BJ: Chemokines. Blood 90(3):909–928, 1997. up to 18 hours after late-afternoon dosing of plerixafor. Transfusion
84. Broxmeyer HE: Chemokines in hematopoiesis. Curr Opin Hematol 54:1263–1268, 2014.
15(1):49–58, 2008. 102. Lefrere F, Mauge L, Rea D, et al: A specific time course for mobilization
85. King AG, Horowitz D, Dillon SB, et al: Rapid mobilization of murine of peripheral blood CD34+ cells after plerixafor injection in very poor
hematopoietic stem cells with enhanced engraftment properties and mobilizer patients: impact on the timing of the apheresis procedure.
evaluation of hematopoietic progenitor cell mobilization in rhesus Transfusion 53:564–569, 2013.
monkeys by a single injection of SB-251353, a specific truncated form 103. Flommersfeld S, Bakchoul T, Bein G, et al: A single center comparison
of the human CXC chemokine GRObeta. Blood 97(6):1534–1542, between three different apheresis systems for autologous and allogeneic
2001. stem cell collections. Transfus Apher Sci 49:428–433, 2013.
86. Pruijt JF, van Kooyk Y, Figdor CG, et al: Anti-LFA-1 blocking antibod- 104. Goldberg SL, Mangan KF, Klumpp TR, et al: Complications of periph-
ies prevent mobilization of hematopoietic progenitor cells induced by eral blood stem cell harvesting: review of 554 PBSC leukaphereses. J
interleukin-8. Blood 91(11):4099–4105, 1998. Hematother 4(2):85–90, 1995.
87. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 105. Madero L, Diaz MA, Benito A, et al: Non-tunneled catheters for the
4(7):540–550, 2004. collection and transplantation of peripheral blood stem cells in children.
88. Deol A, Abrams J, Masood A, et al: Long-term follow up of patients Bone Marrow Transplant 20(1):53–56, 1997.
proceeding to transplant using plerixafor mobilized stem cells and 106. Rowley SD, Yu J, Heimfeld S, et al: Trafficking of CD34+ cells into the
incidence of secondary myelodysplastic syndrome/AML. Bone Marrow peripheral circulation during collection of peripheral blood stem cells
Transplant 48:1112–1116, 2013. by apheresis. Bone Marrow Transplant 28(7):649–656, 2001.
89. Barlogie B, Tricot G, Haessler J, et al: Cytogenetically defined 107. Sierra J, Storer B, Hansen JA, et al: Transplantation of marrow cells
myelodysplasia after melphalan-based autotransplantation for multiple from unrelated donors for treatment of high-risk acute leukemia: the
myeloma linked to poor hematopoietic stem-cell mobilization: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.
Arkansas experience in more than 3,000 patients treated since 1989. Blood 89(11):4226–4235, 1997.
Blood 111:94–100, 2008. 108. Heimfeld S: HLA-identical stem cell transplantation: is there an optimal
90. Liles WC, Rodger E, Broxmeyer HE, et al: Augmented mobilization CD34 cell dose? Bone Marrow Transplant 31(10):839–845, 2003.
and collection of CD34+ hematopoietic cells from normal human 109. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment
volunteers stimulated with granulocyte-colony-stimulating factor kinetics as a function of the CD34 content of peripheral blood
by single-dose administration of AMD3100, a CXCR4 antagonist. progenitor cell collections in 692 patients after the administration of
Transfusion 45(3):295–300, 2005. myeloablative chemotherapy. Blood 86(10):3961–3969, 1995.
91. DiPersio JF, Stadtmauer EA, Nademanee A, et al: Plerixafor and G-CSF 110. Pecora AL, Preti RA, Gleim GW, et al: CD34+CD33- cells influence
versus placebo and G-CSF to mobilize hematopoietic stem cells for days to engraftment and transfusion requirements in autologous blood
autologous stem cell transplantation in patients with multiple myeloma. stem-cell recipients. J Clin Oncol 16(6):2093–2104, 1998.
Blood 113(23):5720–5726, 2009. 111. Dercksen MW, Rodenhuis S, Dirkson MK, et al: Subsets of CD34+
92. DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective random- cells and rapid hematopoietic recovery after peripheral-blood stem-cell
ized double-blind placebo-controlled trial of plerixafor plus granulocyte transplantation. J Clin Oncol 13(8):1922–1932, 1995.
colony-stimulating factor compared with placebo plus granulocyte 112. Sharma M, Afrin F, Satija N, et al: Stromal-derived factor-1/CSCR4
colony-stimulating factor for autologous stem-cell mobilization and signaling: indispensable role in homing and engraftment of hematopoi-
transplantation for patients with non-Hodgkin’s lymphoma. J Clin etic stem cells in bone marrow. Stem Cells Dev 20(6):933–946, 2011.
Oncol 27(28):4767–4773, 2009. 113. Torlen J, Ringden O, Rademacher JL, et al: Low CD34 dose is associ-
93. Micallef IN, Stiff PJ, DiPersio JF, et al: Successful stem cell remobiliza- ated with poor survival after reduced-intensity conditioning allogeneic
tion using plerixafor (Mozobil) plus granulocyte colony-stimulating transplantation for acute myeloid leukemia and myelodysplastic
factor in patients with non-Hodgkin lymphoma: results from the syndrome. Biol Blood Marrow Transplant 20:1418–1425, 2014.
plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow 114. Brenner MK, Rill DR, Moen RC, et al: Gene-marking to trace origin
Transplant 15(12):1578–1586, 2009. of relapse after autologous bone-marrow transplantation. Lancet
94. MacFarland R, Hard ML, Scarborough R, et al: A pharmacokinetic 341(8837):85–86, 1993.
study of plerixafor in subjects with varying degrees of renal impairment. 115. Shimoni A, Korbling M: Tumor cell contamination in re-infused stem
Biol Blood Marrow Transplant 16(1):95–101, 2010. cell autografts: does it have clinical significance? Crit Rev Oncol Hematol
95. Malik S, Bolwell B, Rybicki L, et al: Apheresis days required for 41(2):241–250, 2002.
harvesting CD34+ cells predicts hematopoietic recovery and survival 116. Sharp JG, Kessinger A, Mann S, et al: Outcome of high-dose therapy
following autologous transplantation. Bone Marrow Transplant and autologous transplantation in non-Hodgkin’s lymphoma based on
46(12):1519–1525, 2011. the presence of tumor in the marrow or infused hematopoietic harvest.
96. Fraipont V, Sautois B, Baudoux E, et al: Successful mobilization of J Clin Oncol 14(1):214–219, 1996.
peripheral blood HPCs with G-CSF alone in patients failing to achieve 117. Brugger W, Bross KJ, Glatt M, et al: Mobilization of tumor cells and
sufficient numbers of CD34 cells and/or CFU-GM with chemotherapy hematopoietic progenitor cells into peripheral blood of patients with
and G-CSF. Transfusion 40(3):339–347, 2000. solid tumors. Blood 83(3):636–640, 1994.